Fabrinet and Monopar Therapeutics see share price declines

Fabrinet shares fell 23.4% this week following its fiscal fourth quarter earnings report. Despite revenue surging 45% to $1.32 billion and adjusted earnings per share rising 54.7% to $4.10—both exceeding analyst estimates—investors reacted negatively. The decline is attributed to high valuation expectations for AI-related stocks and concerns regarding the sustainability of growth and declining year-over-year gross margins, which dropped to 12.2%.

Separately, Monopar Therapeutics shares declined 3.9% during Friday trading. The company, which has a market capitalization of approximately $722.61 million, has seen mixed analyst sentiment recently. While some firms like BTIG Research and HC Wainwright have issued buy ratings with increased price targets, Cantor Fitzgerald recently downgraded the stock from overweight to neutral.